# Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)

> **NCT01420874** · PHASE1 · COMPLETED · sponsor: **Barbara Ann Karmanos Cancer Institute** · enrollment: 15 (actual)

## Conditions studied

- Colorectal Cancer
- Cancer of Pancreas
- Pancreatic Neoplasm
- Malignant Neoplasm of Large Intestine
- Malignant Tumor of Colon
- Colon Carcinoma
- Cancer of Colon
- Pancreatic Cancer

## Interventions

- **DRUG:** FOLFOX6
- **BIOLOGICAL:** EGFRBi armed ATC Infusions

## Key facts

- **NCT ID:** NCT01420874
- **Lead sponsor:** Barbara Ann Karmanos Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-08-17
- **Primary completion:** 2020-10-19
- **Final completion:** 2020-10-19
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2023-05-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01420874

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01420874, "Anti-CD3 x Anti-Erbitux® Armed Activated T Cells (Phase Ib) for Gastrointestinal (GI Cancer)". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01420874. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*